Swiss Pharma Exports to U.S. Spike Ahead of Trump’s Tariffs

Switzerland’s export engine accelerated sharply in September, driven by a rush of pharmaceutical shipments to the United States as drugmakers scrambled to get ahead of President Donald Trump’s next wave of trade tariffs. Official data show that Swiss exports to the U.S. surged nearly 43 percent month-on-month, even as other sectors were hit hard by existing duties and rising trade uncertainty.

Pharma Drives September Surge

The rebound marks a striking contrast with August’s export slump, when the U.S. imposed a 39 percent blanket tariff on Swiss goods that disrupted most major export categories. Pharmaceuticals, however, were initially exempt—giving companies such as Roche and Novartis a final window to ship high-value treatments before new penalties took effect.

At the end of September, the Trump administration confirmed that, beginning October 1, it would introduce a 100 percent tariff on branded or patented drugs unless the manufacturer had established—or broken ground on—a production facility in the United States. In response, Swiss pharmaceutical giants ramped up their exports, ensuring that critical inventories reached the U.S. ahead of the new tariff deadline.

Chemical and pharmaceutical products, which account for over half of Switzerland’s total export value, rose 5.1 percent in nominal terms in September. This surge helped lift Switzerland’s overall exports by 3.4 percent, despite the ongoing trade headwinds.

Winners and Losers in a Tight Trade Window

While drug companies benefited from temporary exemptions, other Swiss sectors weren’t as fortunate. Luxury watch exports to the U.S. fell by more than 50 percent, their second consecutive monthly decline, as the 39 percent tariff hit the precision manufacturing sector particularly hard.

Jewelry, vehicles, and specialty chemical exports performed modestly, but the broader picture shows a country racing to adapt to shifting U.S. trade priorities. The surge in pharmaceutical shipments in late September functioned as a last-minute reprieve before heavier restrictions took effect in October.

Companies Position for the Long Game

Major pharmaceutical firms appear better prepared than most industries to weather tariff disruptions. Both Roche and Novartis have publicly noted that they are expanding their U.S. manufacturing footprints—investments that could shield future sales from high import duties.

“These measures are about locking in market access,” explained a Zurich-based trade analyst. “The pharma sector can absorb short-term shipping costs if it means securing tariff-free operations in the long run.”

The broader shift may accelerate a trend in trade geopolitics: multinational corporations relocating production to remain in compliance with protectionist rules while maintaining cross-border market reach.

A Narrowing Trade Balance

Despite the export surge, Switzerland’s trade surplus narrowed to CHF 2.8 billion in September, the smallest since May, as imports jumped nearly 9.4 percent on the back of chemical and jewelry purchases. Still, the record jump in U.S.-bound exports underscores how Swiss businesses are positioning themselves strategically amid rising uncertainty.

For now, the trade data reveal both the agility and vulnerability of Switzerland’s export economy—one of Europe’s most globally integrated. As October’s tariff wave rolls in, the question is whether the September rush represents resilience or merely a pause before a deeper slowdown.

Exporting Procedures Course

Learn from our esteemed instructor who brings you the critical Do’s and Don’ts of Exporting, providing you with actionable insights that bolster your proficiency and confidence in handling every facet of exporting. You’ll gain practical skills that deepen your understanding of the export process and equip you to overcome challenges with ease.

Learn More